Quantcast

Latest Ipilimumab Stories

c7d7d7588c7904c027290ba4e1c2ec19
2011-06-06 12:35:00

A new study found that people with advanced melanoma who were treated with Bristol-Myers Squibb Co.'s Yervoy plus chemotherapy lived an average of two months longer than people who got chemotherapy alone. The study is the first to show that combining chemotherapy and an immune-system treatment is safe and effective for patients with advanced melanoma. It is also the second major trial to show Yervoy (ipilimumab), a new type of immunotherapy drug, can improve survival in patients with the...

2011-04-28 00:15:44

Like brainy bookworms unprepared for the rough and tumble of post-graduation life, white blood cells trained by scientists to attack tumors tend to fade away quickly when injected into cancer patients. Dana-Farber Cancer Institute scientists, however, have developed a technique that can cause such cells to survive in patients' bloodstreams for well over a year, in some cases, without the need of other, highly toxic treatments, a new study shows. In a paper published in the Apr. 27 issue of...

f2d1d174e9ad266b2a3df2720b6258b21
2011-03-26 08:45:00

A drug from Bristol-Myers Squibb Co. shown to help prolong the lives of people suffering from advanced skin cancer has been approved by the US Food and Drug Administration on Friday.The injectable drug, called Yervoy (ipilimumab), is used for late-stage melanoma. Bristol-Myers Squibb aims to use the drug to harness the body's immune system to target and attack melanoma tumors."Yervoy is the first therapy approved by the FDA to clearly demonstrate that patients with metastatic melanoma live...

2011-03-25 19:04:34

First drug approved in more than a decade The U.S. Food and Drug Administration today approved the use of ipilimumab for the treatment of previously treated metastatic melanoma. It is the first drug approved for metastatic, or advanced, melanoma is more than a decade. "Ipilimumab is the first in a new class of drugs that has been shown to offer a survival benefit for metastatic melanoma, which is often a fatal disease, and hopefully, this will lead to the development of related treatments for...

2011-03-25 11:23:00

Melanoma patients lived longer with treatment SILVER SPRING, Md., March 25, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Yervoy (ipilimumab) to treat patients with late-stage (metastatic) melanoma, the most dangerous type of skin cancer. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Melanoma is the leading cause of death from skin disease. An estimated 68,130 new cases of melanoma were diagnosed in the United States during 2010 and...

2010-12-09 17:22:28

Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung...

2010-11-03 05:00:00

CLEVELAND, Nov. 3, 2010 /PRNewswire/ -- From pill-sized cameras to radioactive compounds that let doctors "see" inside a patient's brain, Cleveland Clinic's Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases. The list of breakthrough devices and therapies was selected by a panel of Cleveland Clinic physicians and scientists and unveiled during Cleveland Clinic's 2010 Medical Innovation Summit. The Top 10 Medical...

2010-09-09 11:34:00

HACKENSACK, N.J., Sept. 9 /PRNewswire/ -- Researchers from the John Theurer Cancer Center at Hackensack University Medical Center played an important role in a study that led to the Food & Drug Administration's (FDA) recent fast tracking of ipilimumab, a promising treatment for metastatic melanoma. The FDA based its decision largely on the results of a pivotal study published in the New England Journal of Medicine on August 19, 2010 - the same day the agency accepted Bristol-Myers...

2010-08-26 14:03:25

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma. Investigators at Memorial Sloan-Kettering Cancer Center and colleagues at other cancer centers have published their findings in the August 26 edition of the New England Journal of Medicine. "Metastatic melanoma is a very challenging disease to treat and there have been no significant...

2010-08-26 14:00:17

Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial. Results of the trial of PLX4032, an inhibitor of a protein called BRAF that is overactive in more than half of all melanomas, appear in the August 26 New England Journal of Medicine. "Metastatic melanoma has a devastating prognosis and is one of the top causes of cancer death in young patients," says Keith...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related